Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667787 | SCV000792291 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001067227 | SCV001232274 | pathogenic | not provided | 2023-12-09 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 575 of the USH2A protein (p.Cys575Tyr). This variant is present in population databases (rs483353054, gnomAD 0.003%). This missense change has been observed in individuals with Usher syndrome (PMID: 21569298, 24944099, 25425308, 28894305). ClinVar contains an entry for this variant (Variation ID: 552511). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt USH2A protein function with a positive predictive value of 95%. This variant disrupts the p.Cys575 amino acid residue in USH2A. Other variant(s) that disrupt this residue have been observed in individuals with USH2A-related conditions (PMID: 15325563), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001073924 | SCV001239489 | pathogenic | Retinal dystrophy | 2018-06-26 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000667787 | SCV002809689 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2021-08-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003451662 | SCV004182501 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001271239 | SCV004182502 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003451662 | SCV004207705 | pathogenic | Retinitis pigmentosa 39 | 2024-02-29 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001271239 | SCV001452256 | pathogenic | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |